参考文献/References:
[1] 康锋,代凤霞.乳腺癌组织中孕激素受体、人表皮生长因子受体-2检测联合动态增强磁共振成像对乳腺癌术后复发时间的预测价值[J].陕西医学杂志,2022,51(11):1437-1440,1452.
[2] MA G,LIU C,LIAN W,et al.18F-FLT PET/CT imaging for early monitoring response to CDK4/6 inhibitor therapy in triple negative breast cancer[J].Ann Nucl Med,2021,35(5):600-607.
[3] GUAY E,CORDEIRO E,ROBERTS A.Time to treatment and hospital visits for patients undergoing neoadjuvant chemotherapy for breast cancer in a single payer system[J].J Surg Oncol,2022,125(5):824-830.
[4] CHEN D,SONG X,ZHANG Y,et al.Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion:Less is more[J].Future Oncol,2018,14(21):2131-2138.
[5] 王景民,马曼曼,高孟秋.结核感染T细胞斑点试验在鉴别结核性与恶性胸腔积液中的价值研究[J].陕西医学杂志,2021,50(9):1147-1149,1153.
[6] 贾俊斌,顾岩.非小细胞肺癌相关恶性胸腔积液抗血管生成治疗与免疫治疗研究进展[J].中华肿瘤防治杂志,2022,29(23):1702-1708.
[7] 吴国成,陈焕,王志国,等.内科胸腔镜联合肿瘤标志物在不明原因胸腔积液鉴别诊断的应用[J].中国临床医生杂志,2021,49(9):1044-1046.
[8] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):692-754.
[9] 周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,2007:45-47.
[10] 陈金蓉,唐小涵,陈仕高,等.乳腺癌雌激素受体和人类表皮生长因子受体-2联合表达与淋巴结转移相关性分析[J].成都医学院学报,2022,17(6):702-705.
[11] 何婷,刘晓芳.基于细胞介导的免疫应答观察逐水饮治疗肺癌胸腔积液疗效及机制探究[J].陕西中医,2021,42(3):288-292.
[12] 杨朝晖,林雅,曹学全,等.乳腺癌转移性胸腔积液14例临床病理学特征及分子分型分析[J].临床与实验病理学杂志,2022,38(1):85-88.
[13] SCHRIJVER W A,SCHUURMAN K,ROSSUM A,et al.Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy[J].Oncotarget,2017,8(33):55550-55561.
[14] 韩菲菲,丁可,张瑞,等.铂类灌注联合体外胸腹腔热疗与铂类体腔热灌注治疗恶性胸腹腔积液疗效比较[J].海南医学,2020,31(13):1683-1686.
[15] MATSUMOTO K,NAKAMURA Y,INAGAKI Y,et al.Mediastinal undifferentiated pleomorphic sarcoma with pleural effusion cytopathologically misdiagnosed as epithelial malignant pleural mesothelioma:An autopsy case report[J].Thorac Cancer,2021,12(7):1137-1140.
[16] YEU K J,PARK J,CHOI J E,et al.Intrathoracic paclitaxel chemotherapy for malignant pleural effusion in breast cancer[J].Cancer Res,2016,76(4):25.
[17] 黄艳,张莹,宋瑶,等.乳腺癌脑转移放疗的临床疗效和预后分析[J].实用癌症杂志,2022,37(5):813-818.
[18] 袁琪,王伟,徐春华.晚期非小细胞肺癌恶性胸腔积液IL-6水平与EGFR-TKIs治疗疗效及预后的关系[J].现代肿瘤医学,2022,30(7):1224-1228.
[19] ZHU Z,LI S,WU D,et al.High-throughput and label-free enrichment of malignant tumor cells and clusters from pleural and peritoneal effusions using inertial microfluidics[J].Lab Chip,2022,22(11):2097-2106.
[20] CHANGCHIEN C Y,CHEN Y,CHANG H H,et al.Effect of malignant-associated pleural effusion on endothelial viability,motility and angiogenesis in lung cancer[J].Cancer Sci,2020,111(10):3747-3758.
[21] 徐晓飞,李阳,陈凌云,等.预后营养指数和控制营养状态在乳腺癌中的研究进展[J].肿瘤防治研究,2022,49(9):961-964.
[22] 郎然,金建军,张彭辉,等.白蛋白结合型紫杉醇联合顺铂对非小细胞肺癌引起的恶性胸腔积液的疗效[J].广东医学,2018,39(15):2369-2372,2376.
[23] SHI X Y,YI F S,WANG Z,et al.Prognostic value of a new score using serum alkaline phosphatase and pleural effusion lactate dehydrogenase for patients with malignant pleural effusion[J].Thorac Cancer,2020,11(2):320-328.
[24] 袁晃堆,肖燕青.肿瘤标志物及生化指标联合检测在良恶性胸腹腔积液诊断中的作用[J].中外医疗,2014,26(32):26-27,29.
[25] JIN S,ZHOU C,HOU X,et al.A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer[J].Transl Lung Cancer Res,2020,9(4):1507-1515.
相似文献/References:
[1]乔亚舜,吴瑛琦.乳腔镜腋窝淋巴结清扫术治疗早期乳腺癌临床研究[J].陕西医学杂志,2019,(4):473.
QIAO Yashun,WU Yingqi..Clinical study of mammoscopic axillary lymph node dissection for early breast cancer patients[J].,2019,(2):473.
[2]谭兴利,陆伟辉,汤学文,等.乳腺癌患者超声检查中PSV、RI值与术后组织中MMP11、VEGF表达的相关性探讨[J].陕西医学杂志,2019,(5):617.
[3]韩丕华,宋张骏△,杨晓民,等.乳腺超声造影联合细针穿刺定位活检在判定乳腺癌新辅助化疗后腋窝淋巴结性质中的临床研究*[J].陕西医学杂志,2019,(7):842.
HAN Pihua,SONG Zhangjun,YANG Xiaomin,et al.Application of breast contrast-enhanced ultrasonography combined with fine needle aspiration biopsy in determining the axillary lymph node properties after neoadjuvant chemotherapy for breast cancer[J].,2019,(2):842.
[4]蒋 敢,王 军,王会东△.舒芬太尼联合罗哌卡因肋间神经阻滞对乳腺癌患者术后镇痛、免疫功能及应激反应的影响*[J].陕西医学杂志,2019,(8):1077.
JIANG Gan,WANG Jun,WANG Huidong..Effect of sufentanil plus ropivacaine intercostal nerve block on postoperative analgesia, immunity and stress response in patients with breast cancer[J].,2019,(2):1077.
[5]王群拴,黎小花△.核磁共振结合血清肿瘤标志物及细胞因子检测在〖JZ〗乳腺癌诊断中的应用价值研究*[J].陕西医学杂志,2019,(10):1295.
[6]韩丕华,袁 权△.乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值*[J].陕西医学杂志,2020,49(7):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
HAN Pihua,YUAN Quan..Predictive value of IL-22 expression level in breast cancer patients for pathological complete remission after neoadjuvant chemotherapy[J].,2020,49(2):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
[7]韩金怡,苏志勇.21基因检测对早期Luminal A型乳腺癌治疗指导作用研究[J].陕西医学杂志,2021,50(9):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
HAN Jinyi,SU Zhiyong.Guiding role of 21-gene detection in treatment of early Luminal type A breast cancer[J].,2021,50(2):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
[8]王景民,马曼曼,高孟秋.结核感染T细胞斑点试验在鉴别结核性与恶性胸腔积液中的价值研究[J].陕西医学杂志,2021,50(9):1147.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.026]
[9]白玲娇,陈小军,王 婷.乳腺癌超声弹性成像评分与免疫组化指标表达水平相关性分析[J].陕西医学杂志,2021,50(10):1239.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.015]
[10]郑 超,苏 娟,盛杰鑫,等.乳腺癌患者病灶血流时间-信号强度曲线类型、表观弥散系数与化疗疗效相关性分析[J].陕西医学杂志,2021,50(12):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
ZHENG Chao,SU Juan,SHENG Jiexin,et al.Correlation between focal blood flow time-signal intensity curve type,apparent diffusion coefficient and chemotherapy efficacy in breast cancer patients[J].,2021,50(2):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]